Leo Wealth LLC bought a new stake in GSK PLC Sponsored ADR (NYSE:GSK – Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 18,816 shares of the pharmaceutical company’s stock, valued at approximately $906,000.
Several other hedge funds have also recently added to or reduced their stakes in the business. Kahn Brothers Group Inc. bought a new stake in GSK in the second quarter valued at $8,305,000. Nvest Financial LLC bought a new position in shares of GSK during the second quarter valued at $2,236,000. Keystone Financial Planning Inc. lifted its holdings in shares of GSK by 3,114.8% during the second quarter. Keystone Financial Planning Inc. now owns 195,590 shares of the pharmaceutical company’s stock valued at $10,253,000 after acquiring an additional 189,506 shares during the period. Baird Financial Group Inc. lifted its holdings in shares of GSK by 110.3% during the second quarter. Baird Financial Group Inc. now owns 50,129 shares of the pharmaceutical company’s stock valued at $2,628,000 after acquiring an additional 26,290 shares during the period. Finally, NewEdge Advisors LLC boosted its stake in shares of GSK by 842.9% in the 2nd quarter. NewEdge Advisors LLC now owns 953,574 shares of the pharmaceutical company’s stock valued at $49,986,000 after purchasing an additional 852,437 shares in the last quarter. Institutional investors and hedge funds own 15.74% of the company’s stock.
Wall Street Analyst Weigh In
Several equities research analysts have recently weighed in on the stock. Jefferies Financial Group reaffirmed a “buy” rating on shares of GSK in a report on Monday, September 28th. Wolfe Research initiated coverage on shares of GSK in a report on Friday, October 9th. They set an “outperform” rating and a $70.00 price target for the company. Barclays reissued a “sell” rating on shares of GSK in a report on Monday, September 7th. Deutsche Bank Aktiengesellschaft restated a “neutral” rating on shares of GSK in a research report on Tuesday, September 29th. Finally, Berenberg Bank reaffirmed a “buy” rating on shares of GSK in a research note on Tuesday, October 6th. Four research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $55.33.
Check Out Our Latest Stock Report on GSK
GSK Trading Up 0.7%
Shares of GSK opened at $51.10 on Tuesday. The company has a debt-to-equity ratio of 0.81, a quick ratio of 0.52 and a current ratio of 0.82. The company has a market cap of $103.37 billion, a price-to-earnings ratio of 15.98, a PEG ratio of 2.28 and a beta of 0.33. The stock has a fifty day moving average price of $49.58 and a two-hundred day moving average price of $52.36. GSK PLC Sponsored ADR has a 52-week low of $42.88 and a 52-week high of $61.69.
GSK (NYSE:GSK – Get Free Report) last announced its earnings results on Tuesday, July 28th. The pharmaceutical company reported $1.36 EPS for the quarter, topping the consensus estimate of $1.27 by $0.09. GSK had a return on equity of 43.23% and a net margin of 14.56%. The company had revenue of $11.14 billion for the quarter, compared to analysts’ expectations of $11.02 billion. During the same quarter in the prior year, the business earned $0.47 earnings per share. The business’s revenue for the quarter was up 5.3% on a year-over-year basis. Analysts predict that GSK PLC Sponsored ADR will post 4.78 EPS for the current fiscal year.
GSK Profile
GSK plc, formerly GlaxoSmithKline, is a global biopharmaceutical company headquartered in Brentford, England. The company focuses on researching, developing and commercializing medicines and vaccines designed to prevent and treat infectious diseases, respiratory conditions, immune-related disorders and certain cancers.
Its vaccine portfolio includes products such as Shingrix for shingles, Arexvy for respiratory syncytial virus (RSV) in older adults, and vaccines targeting meningitis, influenza and other infectious diseases.
Featured Stories
- Five stocks we like better than GSK
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK PLC Sponsored ADR (NYSE:GSK – Free Report).
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.
